EO 2002
Alternative Names: EO-2002Latest Information Update: 06 May 2024
At a glance
- Originator Emmecell
- Class Cell therapies; Eye disorder therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Corneal disorders
Most Recent Events
- 30 Apr 2024 Emmecell plans a pivotal phase III trial in the first quarter of 2025
- 28 Oct 2023 No recent reports of development identified for phase-I development in Corneal-disorders in USA (Parenteral, Injection)
- 01 Dec 2022 Emmecell initiates enrolment in a phase I trial Corneal disorders (Monotherapy) in Mexico (Ophthalmic) (NCT05636579)